arthritis

Home/Tag: arthritis

SLRA 2019 EULAR Conference

June 26, 2019 @ 6:00 pm 9:00 pm

St. Louis Rheumatology Association

Wednesday, June 26, 2019

2019 EULAR Conference: Update on Clinical and Lab Research findings for RA, PSA, Lupus

 

Vibeke Strand, M.D.

Presenter: Vibeke Strand, M.D. Adjunct Clinical Professor of Medicine Division of Immunology/Rheumatology, Stanford University

Vibeke Strand, MD, FACP, FACR is theAdjunct Clinical Professor for the Division of Immunology/Rheumatology at  Stanford University and a Biopharmaceutical Consultant

 

 

6:15 – 7:00 pm Registration

7:00 – 9:00 pm Presentation and dinner

Preston Restaurant (Chase Park Plaza)
212 Kingshighway Blvd, St Louis, MO 63108

Preston Restaurant

212 Kingshighway Blvd
St. Louis, 63108 United States
Google Map
(314) 633-7800
https://www.theprestonstl.com/

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Washington University School of Medicine, Continuing Medical Education and St. Louis Rheumatology Association.  Washington University is accredited by the ACCME to provide continuing medical education for physicians.  Washington University designates this live activity for a maximum of _1_ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities.  All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations.  Any potential conflicts were addressed and resolved.  All members of the CME department have nothing to disclose.  Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients.  All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests. These presentations are the views and experiences of the presenters.  The presenters’ views do not represent the policy or position of Washington University School of Medicine.  Washington University School of Medicine, Continuing Medical Education, is the sponsor for CME credits.

St. Louis Rheumatology Association

http://internalmed.slu.edu/

2019 Walk to Cure Arthritis

Join PSN and say “yes” to helping create a world where people don’t have to struggle to button their shirt, tie their shoe, pick up their child or grandchild or play with their friends. It’s up to us to help those with arthritis gain access to life-changing information and resources so they can better manage their disease and live full, healthy lives, plus accelerate the path to better treatments and eventually a cure through cutting-edge research.

This years registration for the WALK includes FREE admission into the Miners game. The Walk will start inside the stadium and will go around the concourse, to the outfield gate (not yet on the field). Then it’ll enter the outfield gate and walk around the track and onto home plate. The Walk itself starts at 6:00 p.m. but check-in for the Walk starts at 5:30 p.m.

Join PSN in the Walk to Cure Arthritis, April 26

Did you know that arthritis is the #1 cause of disability in the United States, affecting more than 50 million people? Our friends at The Arthritis Foundation are committed to finding a cure for the millions of people who suffer from arthritis pain, including 300,000 children and their families.

Premier Specialty Network is enthusiastic to be one of the local sponsors at this year’s Walk to Cure Arthritis – Southern Illinois on Friday, April 26th! The Walk to Cure Arthritis is the Arthritis Foundation’s annual fundraising 5K event that rallies communities together and raises funds to conquer arthritis for good! Whether you have a family member or loved one who suffers from arthritis or are simply looking for a fun charity event, the Walk to Cure Arthritis is a great way to get moving in support of a worthy cause!

Join PSN and say “yes” to helping create a world where people don’t have to struggle to button their shirt, tie their shoe, pick up their child or grandchild or play with their friends. It’s up to us to help those with arthritis gain access to life-changing information and resources so they can better manage their disease and live full, healthy lives, plus accelerate the path to better treatments and eventually a cure through cutting-edge research.

This years registration for the WALK includes FREE admission into the Miners game. The Walk will start inside the stadium and will go around the concourse, to the outfield gate (not yet on the field). Then it’ll enter the outfield gate and walk around the track and onto home plate. The Walk itself starts at 6:00 p.m. but check-in for the Walk starts at 5:30 p.m.

If you set up a team, like you had last year, everyone who registers for the walk will get into the game for FREE! When you check-in, you’ll get your free ticket with a designated seat to watch the game. Your booth will also be inside the stadium and can be set up until the end of the game.

The baseball stadium also has fireworks every Friday night!!

Event Location

Rent One Park
1000 Miners Drive
Marion, IL 62959

Event Schedule

Friday, April 26, 2019

  • 5:00 p.m. – Check-in

If you are unable to join us in the WALK this year, please consider making a donation to the fight to cure arthritis.

We can’t wait to see you at Walk to Cure Arthritis this year – we invite you all to come together to register, fund raise and walk, all while having a great time; because we believe that another step equals another victory!

2019 Juvenile Arthritis Symposium

St. Louis University School of Medicine

Arthritis Foundation – Missouri

Saturday, March 2, 2019

Program Information

An estimated 300,000 children in the U.S. — that’s 1 in 250 kids — are affected by some form of JA. This disease takes a unique physical and emotional toll on kids, often resulting in debilitating pain and feelings of loneliness or depression. JA can make it especially challenging for kids to say Yes — Yes to playing, Yes to hanging out with friends, Yes to spending time with family, Yes to being a kid!

Presented by

Baptist Logo

Please join the Arthritis Foundation for the 2019 JA Symposium. Dr. Jordan Jones of Children’s Mercy Hospital will speak to families about the latest advancements in pediatric rheumatology. Arthritis Foundation staff will share what we do to try and help you and your family in navigating life with juvenile arthritis. At the end of our program each family will be provided free tickets to the exhibit at Union Station as well as tickets to visit Science City!

There is no cost to attend this event. You must pre-register all members of your family that will be in attendance. Enter the number of people attending the event below and click next. On the second page you will be asked to enter information for all those attending. Once submitted you will receive an email confirming your reservation.

By submitting this form you agree to the JA Day Waiver.

Space is limited. Pre-registration for this free event is mandatory.

If you have any questions please contact Brooke Hilst at bhilst@arthritis.org or 913-259-7153.

Arthritis Foundation Medical Honoree 2018

Arthritis Foundation Medical Honoree 2018

The Arthritis Foundation is honored to feature Dr. Fred Pfalzgraf as the 2018 Medical Honoree for the Walk To Cure Arthritis in Southern Illinois.

Dr. Pfalzgraf is originally from Wisconsin where he graduated from the University of Wisconsin Medical School. He completed his internship and residency at Fizsimons Army Medical Center in Aurora, Colorado, and went on to finish his rheumatology fellowship at the University of Colorado Health Sciences Center in Denver.

He takes great pride in this honor as an avenue to educate the people of Southern Illinois about arthritis in its many forms and to spread awareness of its growing prevalence in our society today. Currently, Dr. Pfalzgraf is working as a rheumatologist for Premier Specialty Network with clinics in Perryville, MO; and, DuQuoin, Benton, Sparta, and Eldorado, IL.

He asks that you join him and his team in supporting the mission of the Arthritis Foundation to serve those living with the daily challenges of arthritis while leading the fight to find a cure.

Please register and/or donate today at:
www.walktocurearthritis.org/southernillinois

Deactivating A Cell Protein May Halt Progress Of Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune disease that leads to inflammation and bone erosion in the joints. One of the hallmarks is swelling and pain caused by white blood cells flooding into the fluid around the joints. Now researchers have shown for the first time that the activation of a single protein on the surface of these cells could be the trigger for the disease.

The cell protein they investigated is toll-like receptor 5 (TLR5) that is found on myeloid – or marrow-derived – cells that migrate from the blood into affected joints.

“TLR5 does it all,” says one of the researchers, Shiva Shahrara, associate professor of rheumatology at the University of Illinois at Chicago College of Medicine.

She and her colleagues write about the study in the Journal of Immunology. They suggest the findings may lead to new drugs that target the cell protein and break the vicious cycle of inflammation and bone degradation in rheumatoid arthritis. Myeloid cells of rheumatoid arthritis patients have far more TLR5 receptors.

When they compared the myeloid cells from the joints of healthy people with those of rheumatoid arthritis sufferers, they found the myeloid cells from the arthritis patients had far more TLR5 on their surfaces.

One of the hallmarks of rheumatoid arthritis is swelling and pain caused by white blood cells flooding into the fluid around the joints. From previous work, they had already established that activation of the receptor leads to abnormal development of blood vessels in the joints of patients with rheumatoid arthritis.

In this latest work, they discovered the receptor also boosts the activity of TNF-alpha, an inflammatory molecule that summons even more myeloid cells into the joints, whereupon they change into osteoclasts, cells that cause bone erosion.

The researchers also carried out a series of experiments to show activating TLR5 triggers several disease processes. For example, they showed if myeloid cells with active TLR5 are placed next to joint fluid taken from rheumatoid arthritis patients, they migrate into the fluid, but switching TLR5 off reduces migration significantly.

In other experiments, the researchers showed that when the joint fluid of patients with rheumatoid arthritis contained myeloid cells with activated TLR5, this increased levels of TNF-alpha, and the myeloid cells of patients taking anti-TNF-alpha drugs have fewer TLR5 receptors. This suggests there is a positive feedback loop between TLR5 and TNF-alpha: when one increases, so does the other, as Prof. Shahrara explains:

“Not only do TLR5 and TNF-alpha regulate each other, but they work synergistically to attract more myeloid cells into the joint, where they are transformed into bone-eroding cells.”

In a final set of experiments, the team showed giving mice with rheumatoid arthritis an antibody to block TLR5 significantly reduced joint swelling and bone erosion compared to mice that did not receive the drug. The team suggests that blocking TLR5 with the antibody reduced myeloid cells migrating into the joints and turning into bone-eroding osteoclasts. Prof. Shahrara believes this means a drug that stops TLR5 activation could slow or even prevent the joint inflammation and bone erosion that occurs in later-stage rheumatoid arthritis. She suggests when the receptor is switched on, it triggers a “vicious feedback loop” that worsens the inflammation and bone erosion of rheumatoid arthritis.

“The receptor is a major driver of inflammation and bone degradation,” she explains. “Blocking this receptor could have significant therapeutic value in interrupting joint swelling and bone loss in patients with rheumatoid arthritis.”

Funds from the National Institutes of Health, the Department of Defense, the American College of Rheumatology and the Arthritis Foundation helped finance the study.

In June 2014, Medical News Today learned how researchers identified the T cells that drive rheumatoid arthritis. Using cutting-edge tetramer technology, the scientists studied how the disease starts, how current therapies may affect the immune response directed to the joint, and how to target these specific cells with drugs.

SOURCE: Medical News Today

Prof. Shahrara says it is as though something in the joint fluid attracts the myeloid cells when their TLR5 receptors are switched on. She suggests perhaps a protein that binds to the receptor is present in the fluid of joints affected by rheumatoid arthritis. Switched on TLR5 may trigger ‘vicious feedback loop’ of inflammation and erosion.

Surgeons Create ‘New’ Knee Cartilage From Stem Cells In Hip

New knee operation that could prevent the development of arthritis

Surgeons in Southampton have pioneered a new knee operation that could prevent the development of arthritis – and extend sporting careers.

The procedure, which is currently being trialed at Southampton General Hospital, involves coating damaged cartilage with stem cells, taken from a patient’s own hip, and surgical glue.

Known as ABICUS – Autologous Bone Marrow Implantation of Cells University Hospital Southampton – the technique, if successful, will regenerate the remaining tissue and create a permanent, “like-for-like” replacement for the first time.

Cartilage is a tough, flexible tissue that covers the surface of joints and enables bones to slide over one another while reducing friction and acting as a shock absorber.

Damage to the tissue in the knee is common and occurs mainly following sudden twists or direct blows, such as falls or heavy tackles playing sports such as football and rugby, but can also develop over time through gradual wear and tear.

Around 10,000 people a year in the UK suffer cartilage damage serious enough to require treatment due to pain, ‘locking’ and reduced flexibility. If left untreated, it can progress to arthritis and severely impair leg movement.

Currently, the most commonly used procedure to repair the injury – microfracture – involves trimming any remaining damaged tissue and drilling holes in the bone beneath the defect via keyhole surgery to promote bleeding and scar tissue to work as a substitute.

However, the technique has variable results, with studies in the US suggesting the procedure offers only a short term benefit (the first 24 months after surgery), and does not lead to the formation of new cartilage.

Sports Medicine Research

Patients who undergo the ABICUS operation have the cartilage cut and tidied and undergo microfracture, but their cartilage tissue is then coated with a substance made up of bone marrow cells, platelet gel and hyaluronic acid.

During the 30-minute procedure, the bone marrow sample is spun in a centrifuge in the operating theatre to give a concentrated amount of the patient’s own stem cells.

These cells are then mixed with the gel and acid to create a ‘glue’ substance which is placed over the cartilage defect and allowed to set.

Gorav Datta, a consultant orthopaedic surgeon at Southampton General Hospital and the study’s principal investigator, said: “The development of this technique and the study we are conducting could revolutionise the treatment of common cartilage injury by creating a like-for-like, identical cartilage replacement for the first time.

“So far, treatments developed to combat the long-term problems associated with cartilage damage have had varied outcomes, resulting in knee pain for many people in older age and shortened careers for many amateur and professional sports players.”

He added: “At present, although the removal of damaged cartilage and microfracture surgery can provide a short-term solution, the chances, particularly for sports players, of developing arthritis in later life or requiring ongoing treatment remain high.”

The study at University Hospital Southampton NHS Foundation Trust will compare the results of 40 patients aged between 18 and 65 years, half who will undergo ABICUS and half microfracture alone.